High Throughput Screening Market - By Products and Services (Consumables, Instruments, Software and Services), By Technology (Cell-based Assays, Lab-on-a-chip), By Application (Drug Discovery), By End-use (CROs), & Forecast, 2023 – 2032

High Throughput Screening Market - By Products and Services (Consumables, Instruments, Software and Services), By Technology (Cell-based Assays, Lab-on-a-chip), By Application (Drug Discovery), By End-use (CROs), & Forecast, 2023 – 2032

High Throughput Screening Market Size

High Throughput Screening Market size was valued at around USD 22.1 billion in 2022 and it is estimated to reach over USD 49.8 billion in 2032. Growing focus towards implementation of ultra high throughput screening (uHTS) techniques that is capable of conducting hundreds of thousands of screening tests per day is augmenting the industry growth.
 

Increased funding and R&D budgets of multinational companies are driving global clinical trials, leading to market growth. HTS is finding expanded applications in stem cell research, toxicology, and other life science fields, contributing to its adoption. Open innovation models and ongoing technological advancements in HTS are further fueling market growth. Therefore, these factors are expected to support the market progression.
 

High-throughput screening (HTS) is a method specifically used for drug discovery that involves automated screening of huge numbers of biological and chemical compounds for a specific biological target. HTS is a preferred method for identification of biologically relevant compounds in drug discovery processes by running millions of chemical and biological tests in a short time span.
 

HTS is increasingly being adopted in research facilities across various domains. The method involves multiple steps, including target identification, assay development, and compound screening, each with varying time, cost, and complexity. Among these steps, assay development for primary and secondary assays is particularly expensive, requiring specialized systems. This cost barrier poses challenges for small-scale labs and academic research facilities with limited budgets.
 

Additionally, multinational pharma companies face increased capital investment and total cost of ownership due to the need for multiple systems. Furthermore, the scarcity of skilled personnel and the significant maintenance costs associated with these instruments are expected to impede market progress.
 

COVID-19 Impact

The HTS method has emerged as a valuable approach for identifying new lead compounds, particularly in the development of antiviral drugs during the pandemic. Global researchers have directed their efforts towards exploring the potential of existing drugs for treating the SARS-CoV-2 virus. The increased research spending on drug development has resulted in a surge in drug discovery and subsequent high adoption of HTS. As a result of these developments, the high throughput screening industry experienced a positive impact during the pandemic.
 

High Throughput Screening Market Trends

The global healthcare sector is facing an increasing demand for effective diagnostic and treatment methods due to the rising incidence and prevalence of various diseases. To meet this demand, there is a growing need for new and improved drugs manufactured with advanced technologies. However, drug development and discovery is a complex and time-consuming process, typically taking 10-15 years and costing billions of dollars. In this context, high throughput screening (HTS) has emerged as a preferred method among researchers. By screening hundreds of thousands of samples per day, HTS helps to minimize the lengthy drug development timeline.
 

HTS utilizes various detection techniques, including fluorescence polarization (FP), fluorescence intensity distribution analysis (FIDA), and biochemical assays, along with recent technological advancements such as miniaturization and the adoption of artificial intelligence. These advancements contribute to reducing the time required for drug development. Additionally, the increasing number of clinical trials is resulting in a higher number of drug targets for screening, further driving the adoption of HTS in the drug discovery process. As a result, all these factors are projected to fuel the growth of the high throughput screening market in the forecast period.
 

High Throughput Screening Market Analysis

Based on products and services, the high throughput screening market is categorized into consumables, software and services and instruments. The software and services segment held significant share in 2022 and is projected to witness fastest growth with a CAGR of 9.1% over the forecast period. HTS target profiling assays, assay development and testing, data-validation, and storage, and hit validation, among others are key services provided by players operating in the industry. Further, use and adoption of advanced data processing software for automation of different liquid handling systems is a key factor driving the market expansion.
 

Based on technology, the high throughput screening market is segmented into cell-based assays, lab-on-a-chip, label-free technology, and ultra high throughput screening. The cell-based assays segment was valued at around USD 12.6 billion in 2022. This is primarily attributed to the fact that in contrast to traditional biochemical assays, cell-based assays can generate and facilitate more complex biologically relevant data and evaluate compound characteristics simultaneously. Large number of companies are undergoing the transition from 2D-based cell culture to 3D-based cell culture as it offers more approximate physical environment along with accurate results in drug screening studies.
 

Based on application, the high throughput screening market is categorized into biochemical screening, drug discovery, life sciences research, and others. The drug discovery segment is projected to reach over USD 31.3 billion in 2032. HTS method is used to test genomics, combinatorial chemistry, and protein libraries for target identification during the drug discovery process. Development of novel drugs for life threatening conditions, reduction in drug developing timeline, and adoption of ultra HTS technique for faster assay screening are other factors supporting the industry expansion. Moreover, notable penetration of 3D-cell cultures for developing new drug molecule is further boosting the market size.
 

Based on end-use, the high throughput screening market is bifurcated into academic and research institutes, contract research organizations, and pharmaceutical & biotechnology companies. Pharmaceutical and biotechnology firms segment was valued at around USD 16.7 billion in 2022. This is primarily attributed to increasing adoption of HTS technologies in drug discovery process in pharma companies globally. Factors such as need for precise, rapid and faster screening of target molecules during drug development process, adoption of uHTS method for screening of large number of chemical and biomarker libraries generated during the research phase is anticipated to propel the segment progression. Additionally, rise in R&D spending by major pharma and biotech companies worldwide is predicted to contribute to industry development.
 

North America held a dominant market share in the global high throughput screening market and is expected to grow at 7.7% CAGR by 2032. The high industry growth is due to numerous factors such as high disease burden rate, technological advancements, increased R&D spending, and industrial collaboration among key players, etc. Additionally, presence of key market players, increase in the incidence and prevalence of chronic diseases, and growing trend of open innovation model is projected to foster the market outlook.
 

Regional government along with venture capital agencies are actively focusing on increasing the research spending for new and improved drug molecules which in turn will boost the adoption of HTS technology. Surging adoption of HTS methods by generic manufacturers for hit identification and target validation throughout the drug development process will fuel the industry development.
 

High Throughput Screening Market Share

Some of the leading players operating in the high throughput screening market include

• Tecan Group Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer Inc.
• Agilent Technologies Inc.
• Thermofisher Scientific Inc.
• Bio-Rad Laboratories 

The market is competitive in nature, with leading players, CROs, regional and local organizations, along with start-ups further consolidating the industry competition. The leading market players are involved in strategic developments including adoption of open innovation models, research and development, mergers, and acquisitions, to improve their market positioning and revenue generating capabilities.
 

High Throughput Screening Industry News

• In February 2023, Beckman Coulter Life Sciences announced a collaboration with analytical technologies company Sciex to receive comprehensive workflows for high-throughput screening, and synthetic biology studies. This strategic move will help company to increase their operational capabilities and enhance their business revenue.
   
• In November 2022, Particle Works, a UK-based company, launched its ALiS – Automated Library Synthesis System. The platform enables automation and HTS of LNP Formulation Screening as well as mRNA candidates in early-stage drug development process. This strategic development helped the company to enhance their portfolio and improve their market presence.
   

High throughput screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Products and Services, 2018 - 2032 (USD Million)

• Consumables
• Instruments
• Liquid Handling Systems
• Others 
• Software and Services

By Technology, 2018 - 2032 (USD Million)

• Cell-based Assays
• 2D Cell Culture
• 3D Cell Culture
  • Scaffold-based Technologies
  • Scaffold-free Technologies
• Reporter based Assays
• Perfusion Cell Culture 
• Lab-on-a-chip
• Label-free Technology
• Ultra High Throughput Screening

By Application, 2018 - 2032 (USD Million)

• Drug Discovery
• Biochemical Screening
• Life Sciences Research
• Others

By End-use, 2018 - 2032 (USD Million)

• Pharmaceutical & Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Peru
  • Chile
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Israel
  • Iran